ATE499942T1 - 2-methylen-19,21-dinor-1alpha-hydroxy- bishomopregnacalciferol - Google Patents

2-methylen-19,21-dinor-1alpha-hydroxy- bishomopregnacalciferol

Info

Publication number
ATE499942T1
ATE499942T1 AT05849207T AT05849207T ATE499942T1 AT E499942 T1 ATE499942 T1 AT E499942T1 AT 05849207 T AT05849207 T AT 05849207T AT 05849207 T AT05849207 T AT 05849207T AT E499942 T1 ATE499942 T1 AT E499942T1
Authority
AT
Austria
Prior art keywords
hydroxy
bishomopregnacalciferol
dinor
1alpha
methylene
Prior art date
Application number
AT05849207T
Other languages
English (en)
Inventor
Hector F Deluca
Lori A Plum
Margaret Clagett-Dame
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of ATE499942T1 publication Critical patent/ATE499942T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
AT05849207T 2004-11-22 2005-11-18 2-methylen-19,21-dinor-1alpha-hydroxy- bishomopregnacalciferol ATE499942T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62995804P 2004-11-22 2004-11-22
PCT/US2005/041888 WO2006057915A2 (en) 2004-11-22 2005-11-18 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol

Publications (1)

Publication Number Publication Date
ATE499942T1 true ATE499942T1 (de) 2011-03-15

Family

ID=36498437

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05849207T ATE499942T1 (de) 2004-11-22 2005-11-18 2-methylen-19,21-dinor-1alpha-hydroxy- bishomopregnacalciferol

Country Status (11)

Country Link
US (1) US8604008B2 (de)
EP (1) EP1827452B1 (de)
JP (1) JP5036548B2 (de)
AT (1) ATE499942T1 (de)
AU (1) AU2005309820B2 (de)
CA (1) CA2588063C (de)
DE (1) DE602005026694D1 (de)
ES (1) ES2358914T3 (de)
MX (1) MX2007006094A (de)
NZ (1) NZ555561A (de)
WO (1) WO2006057915A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057913A2 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-METHYLENE-19-NOR-(20R)-1-α-HYDROXY-BISHOMOPREGNACALCIFEROL
EP1827452B1 (de) 2004-11-22 2011-03-02 Wisconsin Alumni Research Foundation 2-methylen-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol
US8993547B2 (en) * 2011-06-14 2015-03-31 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
CA2062520C (en) 1991-03-11 1998-08-11 Hector F. Deluca Synthesis of 1-alpha-hydroxy-secosterol compounds
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
EP0619306B1 (de) 1993-04-05 1996-09-11 Wisconsin Alumni Research Foundation 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
US5552392A (en) * 1993-11-03 1996-09-03 Wisconsin Alumni Research Foundation Method of treating hypoparathyroidism with (20S) vitamin D compounds
US5891865A (en) * 1996-10-04 1999-04-06 Wisconsin Alumni Research Foundation Treatment of arthritic disease induced by infectious agents
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5936105A (en) * 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
AU7544501A (en) 2000-09-08 2002-03-22 Wisconsin Alumni Res Found 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
MXPA04005652A (es) * 2001-12-13 2005-03-23 Wisconsin Alumni Res Found (2os)-1 alfa-hidroxi-2-metilen-19-nor-bishomopregnacalciferol y sus usos.
US6835723B2 (en) * 2001-12-13 2004-12-28 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
DE60310050T2 (de) * 2002-03-29 2007-07-05 Wisconsin Alumni Research Foundation, Madison Ein verfahren zur herstellung von 1-alpha-hydroxy-2-methylen-19-nor-homopregnacalciferol
US7232810B2 (en) * 2003-08-20 2007-06-19 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin D2 compounds
EP1689412A4 (de) * 2003-11-25 2009-03-11 Wisconsin Alumni Res Found Vitamin-d-analoga zur prävention und behandlung von adipositas
AU2005309819A1 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20S)-1alpha-hydroxy-trishomopregnacalciferol
WO2006057913A2 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-METHYLENE-19-NOR-(20R)-1-α-HYDROXY-BISHOMOPREGNACALCIFEROL
MX2007006542A (es) * 2004-11-22 2007-07-25 Wisconsin Alumni Res Found 2a-metil-19-nor-(20s)-1a-hidroxi-bishomopregnacalciferol y sus usos.
EP1827452B1 (de) 2004-11-22 2011-03-02 Wisconsin Alumni Research Foundation 2-methylen-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol
WO2009086436A1 (en) * 2007-12-28 2009-07-09 Wisconsin Alumni Research Foundation (20s)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs
MX2010007265A (es) * 2007-12-28 2010-11-30 Wisconsin Alumni Res Found Análogos de vitamina d-(20r)-23, 23-difluoro-2-metilen-19-nor-bish omopregnacalciferol.

Also Published As

Publication number Publication date
WO2006057915A2 (en) 2006-06-01
DE602005026694D1 (de) 2011-04-14
NZ555561A (en) 2009-02-28
AU2005309820A1 (en) 2006-06-01
EP1827452A2 (de) 2007-09-05
EP1827452A4 (de) 2009-10-21
AU2005309820B2 (en) 2011-06-23
US8604008B2 (en) 2013-12-10
JP2008520710A (ja) 2008-06-19
CA2588063A1 (en) 2006-06-01
US20060135800A1 (en) 2006-06-22
CA2588063C (en) 2012-10-16
EP1827452B1 (de) 2011-03-02
WO2006057915A3 (en) 2006-07-13
JP5036548B2 (ja) 2012-09-26
MX2007006094A (es) 2007-07-11
ES2358914T3 (es) 2011-05-16

Similar Documents

Publication Publication Date Title
ATE523487T1 (de) 2-methylen-1-alpha-dihydroxy-19,21-dinor-vitami - d3-analoga und ihre anwendung
WO2008035207A3 (en) 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
MX2007006096A (es) 2-metilen-19-nor-(20s)-1a-hidroxi-trishomopregnacalciferol.
WO2006086613A3 (en) 2-METHYLENE-19-NOR- (20S-24S) - 1α, 25-D IHYDROXYVITAMIN-D2
WO2006119309A3 (en) 19,26,27-TRINOR-1α,25-DIHYDROXYVITAMIN D3 COMPOUNDS
MX2009004707A (es) Piridina carboxamides como inhibidores 11-beta-hsd1.
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
ATE554774T1 (de) 2-methylen-19-nor-(20s-24epi)-1alpha,25- dihydrovitamin-d2
PT1902037E (pt) 2,4-diamino-pirimidinas como inibidores de aurora
MX2007006090A (es) 2-metilen-19-nor-(20r)-1a-hidroxi-bishomopregnacalciferol.
TW200738659A (en) Novel compounds
MX2010002296A (es) Inhibidores iv de polimerasa de fosfadiazina hcv.
BRPI0519292A2 (pt) compostos orgÂnicos
UA88956C2 (ru) Синергическая фунгицидная комбинация действующих веществ
SE0302139D0 (sv) Novel compounds
SE0401970D0 (sv) Novel compounds
SE0303541D0 (sv) New compounds
DE50310579D1 (de) Furancarboxamide
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
SE0303280D0 (sv) Novel compounds
ATE499942T1 (de) 2-methylen-19,21-dinor-1alpha-hydroxy- bishomopregnacalciferol
DE50311756D1 (de) Mikrobizide oxathiincarboxamide
WO2008125901A3 (en) 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof
BRPI0507107A (pt) compostos que se ligam a fator de crescimento e métodos de uso

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties